Advancing precision and personalized breast cancer treatment through multi-omics technologies DOI
Chenlu Zhang, Nan Li, Pengxia Zhang

et al.

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(12), P. 5614 - 5627

Published: Jan. 1, 2024

Breast cancer is the most common malignant tumour in women, with more than 685,000 women dying of breast each year. The heterogeneity complicates both treatment and diagnosis. Traditional methods based on histopathology hormone receptor status are now no longer sufficient. Recently, advances multi-omics techniques, including genomic, proteomic, transcriptomic analyses, have deepened our understanding cancer. Combining these approaches allows for precise molecular subtyping, which essential detection key mutations, protein interactions gene expression patterns that highly relevant to different therapeutic strategies. Genomic analyses been effectively identifying mutations Meanwhile, proteomics transcriptomics complement by new targets elucidating dynamics. Integrating conventional diagnostics improves characterisation enables prognostic accuracy comparable established standards response. Existing emerging technologies enable real-time enhanced follow-up data analysis through liquid biopsy artificial intelligence, respectively. Despite clinical implementation challenges, phenotyping offers significant potential precision treatment. This article describes recent subtyping driving innovations optimise patient outcomes further develop personalised medicine context care.

Language: Английский

Advancing precision and personalized breast cancer treatment through multi-omics technologies DOI
Chenlu Zhang, Nan Li, Pengxia Zhang

et al.

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(12), P. 5614 - 5627

Published: Jan. 1, 2024

Breast cancer is the most common malignant tumour in women, with more than 685,000 women dying of breast each year. The heterogeneity complicates both treatment and diagnosis. Traditional methods based on histopathology hormone receptor status are now no longer sufficient. Recently, advances multi-omics techniques, including genomic, proteomic, transcriptomic analyses, have deepened our understanding cancer. Combining these approaches allows for precise molecular subtyping, which essential detection key mutations, protein interactions gene expression patterns that highly relevant to different therapeutic strategies. Genomic analyses been effectively identifying mutations Meanwhile, proteomics transcriptomics complement by new targets elucidating dynamics. Integrating conventional diagnostics improves characterisation enables prognostic accuracy comparable established standards response. Existing emerging technologies enable real-time enhanced follow-up data analysis through liquid biopsy artificial intelligence, respectively. Despite clinical implementation challenges, phenotyping offers significant potential precision treatment. This article describes recent subtyping driving innovations optimise patient outcomes further develop personalised medicine context care.

Language: Английский

Citations

1